Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races

Wu, Peng; Wu, San-Gang; He, Zhen-Yu

doi:10.1016/j.clbc.2023.10.005

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study from Whelan et al found that the 5-year LRR rate was only 2.3% for BC patients undergoing BCS with low risk of LRR (age >55 years, T1N0, grade 1 or 2, ER positive, PR positive, HER2 negative, and Ki67 ≤ 13.25%), suggesting that these patients may be the safe commission of PORT [ 28 ]. Our recent study discovered a notable correlation indicating that higher T2 staging, a negative PR status, and a higher tumor grade were associated with a higher RS [ 29 ]. In this study, 21.8% of patients were in the low-risk RS group.…”

Section: Discussionmentioning

confidence: 99%

21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery

Xie,

Wang,

et al. 2024

The Breast

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery

Xie,

Wang,

et al. 2024

The Breast

View full text Add to dashboard Cite

The Importance of Naming Structural Racism as a Root Cause of Racial Inequities in Breast Cancer Outcomes

Rollin,

Lee-Rey,

Wong-Serrano

et al. 2024

Clinical Breast Cancer

View full text Add to dashboard Cite

How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer

Boér,

Kaposi,

Kocsis

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: The use of the Oncotype DX test reduces the rate of adjuvant chemotherapy recommendations. Few in-depth analyses have been performed on this decision-making process. Methods: We retrospectively analyzed patient data based on available Oncotype DX test results (RS) irrespective of nodal status at a single center. We collected recommendations from six oncologists, first without RS (pre-RS) and then with RS results (post-RS). We investigated changes in recommendations, agreement between oncologist decisions, and the effect of different National Comprehensive Cancer Network (NCCN) recommendation categories (for, against, and considering chemotherapy). Results: Data from 201 patients were included in the analysis. Recommendation of chemotherapy decreased by an average of 39.5%. Agreement improved substantially with RS, with a kappa value pre-RS of 0.37 (fair agreement) and post-RS of 0.75 (substantial agreement). Discordance remained substantial in cases where the NCCN recommendations considered chemotherapy only (32%). Pre-RS consensus against chemotherapy predicted low RS results (50 out of 51 patients). Post-RS consensus was highest in the NCCN chemotherapy recommendation group. Conclusions: The Oncotype DX test substantially improves decision accuracy in recommending adjuvant chemotherapy. It may be further improved with a consensus decision. In the case of pre-RS consensus against chemotherapy, the test can be spared.

show abstract

Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races

Cited by 3 publications

References 28 publications

21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery

21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery

The Importance of Naming Structural Racism as a Root Cause of Racial Inequities in Breast Cancer Outcomes

How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer

Contact Info

Product

Resources

About